Alcobra Hopes To Continue Development In Fragile X On Quality Of Life Findings
This article was originally published in The Pink Sheet Daily
Executive Summary
Israeli firm contends that secondary endpoints address factors that matter most to patients, clinicians and caregivers, even though its metadoxine failed on the primary efficacy measure.
You may also be interested in...
Alcobra’s Pipeline In A Pill Aims To Capture The ADHD Market And More
Founded in 2008, Alcobra has ridden a wave of impressive data, a friendly reception on the public markets, and growing investor interest in its bid to capture the ADHD market. Now, as it nears the start of Phase III for metadoxine, its unrelenting focus is on execution.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.